tirzepatide and fasting Day 3: Mounjaro (Tirzepatide – weekly injection) Class: Dual GLP-1 GIP receptor agonist Avg Weight Loss: ~20% of baseline weight (SURMOUNT-1 trial) FDA Status: Approved for type 2 diabetes; Fast-tracked for Efficacy outcomes of treatment with

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that works by increasing insulin secretion and suppressing glucagon secretion, leading to lower blood sugar levels

In the ever-evolving field of longevity science, Epithalon represents just one of many powerful, healing peptides we can leverage to restore, maintain, and optimize healthspan and lifespan

Pharmacy provider: Retail pharmacies, mail-order pharmacies, and specialty pharmacies all set different markups

Glucagon-like peptide-1 (GLP-1) receptor agonists represent a breakthrough in medically controlled weight loss

Bangha, E., Elsner, P., & Kistler, G

Many patients continue to experience steady weight loss for months at the same dose before requiring an increase